Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)
28.56
-0.13 (-0.45%)
May 13, 2025, 3:00 PM CST
SHA:688180 Revenue
Shanghai Junshi Biosciences had revenue of 500.59M CNY in the quarter ending March 31, 2025, with 31.46% growth. This brings the company's revenue in the last twelve months to 2.07B, up 27.02% year-over-year. In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B with 29.67% growth.
Revenue (ttm)
2.07B
Revenue Growth
+27.02%
P/S Ratio
12.04
Revenue / Employee
802.21K
Employees
2,578
Market Cap
24.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Sichuan Biokin Pharmaceutical | 5.82B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |